These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28395058)

  • 1. Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas.
    Menter T; Trivedi P; Ahmad R; Flora R; Dirnhofer S; Tzankov A; Naresh KN
    Am J Clin Pathol; 2017 Mar; 147(3):292-300. PubMed ID: 28395058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.
    Tandon B; Peterson L; Gao J; Nelson B; Ma S; Rosen S; Chen YH
    Mod Pathol; 2011 Nov; 24(11):1433-43. PubMed ID: 21685909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric analysis of lymphoid enhancer-binding factor 1 in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Amador-Ortiz C; Goolsby CL; Peterson LC; Wolniak KL; McLaughlin JL; Gao J; Chen YH
    Am J Clin Pathol; 2015 Feb; 143(2):214-22. PubMed ID: 25596247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma.
    Menter T; Dirnhofer S; Tzankov A
    J Clin Pathol; 2015 Jun; 68(6):473-8. PubMed ID: 25713417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.
    Patel N; Durkin L; Bodo J; Hsi ED
    Am J Clin Pathol; 2020 Apr; 153(5):646-655. PubMed ID: 31953940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features.
    Soliman DS; Al-Kuwari E; Siveen KS; Al-Abdulla R; Chandra P; Yassin M; Nashwan A; Hilmi FA; Taha RY; Nawaz Z; El-Omri H; Mateo JM; Al-Sabbagh A
    Int J Lab Hematol; 2021 Jun; 43(3):515-525. PubMed ID: 33314668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas.
    Rangan A; Reinig E; McPhail ED; Rech KL
    Hum Pathol; 2022 Mar; 121():29-35. PubMed ID: 35066013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study of LEF1 protein expression in diagnosis and differential diagnosis of lymphoblastic lymphoma/acute lymphoblastic leukemia].
    Chen X; Rui WW; Bi K; Wu YJ; Zhang SX; Zhang L; Yu J; Xiu B; Yi XH; Zeng Y
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):207-212. PubMed ID: 33677883
    [No Abstract]   [Full Text] [Related]  

  • 9. Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study.
    Kıvrak H; Yüksel S; Ateş C; Merter M; Kaygusuz G; Özcan M; Kuzu I
    Turk J Haematol; 2022 Aug; 39(3):178-187. PubMed ID: 34619856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of LEF1 in mantle cell lymphoma.
    O'Malley DP; Lee JP; Bellizzi AM
    Ann Diagn Pathol; 2017 Feb; 26():57-59. PubMed ID: 28038713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
    Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
    Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma.
    Lyapichev KA; Sakhdari A; Khoury JD; O'Malley DP; El Hussein S; Yin CC; Patel KP; Thakral B; Young KH; Medeiros LJ; Konoplev S
    Ann Diagn Pathol; 2020 Dec; 49():151636. PubMed ID: 32977233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of lymphoid enhancer-binding factor 1 and androgen receptor in diagnosing solid pseudopapillary neoplasm of the pancreas on cytopathology.
    McHugh KE; Stelow EB; Harrison GP; Policarpio-Nicolas MLC
    Cancer Cytopathol; 2019 Nov; 127(11):700-707. PubMed ID: 31584754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics.
    Raghavan SS; Saleem A; Wang JY; Rieger KE; Brown RA; Novoa RA
    Am J Surg Pathol; 2020 Oct; 44(10):1413-1418. PubMed ID: 32520758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.
    Yoshino T; Tanaka T; Sato Y
    J Clin Exp Hematop; 2020 Dec; 60(4):124-129. PubMed ID: 32249238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid.
    Wu W; Zhu H; Fu Y; Shen W; Miao K; Hong M; Xu W; Fan L; Young KH; Liu P; Li J
    Oncotarget; 2016 Apr; 7(16):21631-43. PubMed ID: 26950276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.
    Singhi AD; Lilo M; Hruban RH; Cressman KL; Fuhrer K; Seethala RR
    Mod Pathol; 2014 Oct; 27(10):1355-63. PubMed ID: 24658583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic Utility of LEF1 Immunostain in Cytology Specimens of Solid Pseudopapillary Neoplasm of Pancreas].
    Farzaneh T; Nowroozizadeh B; Han M; Lee W
    Acta Cytol; 2021; 65(3):250-256. PubMed ID: 33887729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma.
    Ravindran A; Kurtin PJ; King RL; Yuan J; Feldman AL; Rech KL; McPhail ED; Parikh SA; Ding W; Shi M
    Hum Pathol; 2022 Jul; 125():2-10. PubMed ID: 35421421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
    Ravindran A; Feldman AL; Ketterling RP; Dasari S; Rech KL; McPhail ED; Kurtin PJ; Shi M
    Am J Surg Pathol; 2021 Apr; 45(4):550-557. PubMed ID: 33165091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.